as on September 17, 2025 at 9:39 pm IST
Day's Low
Day's High
1.25%
Downside
2.66%
Upside
52 Week's Low
52 Week's High
53.76%
Downside
86.21%
Upside
Check Intellia Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.2B
EPS (TTM)
-4.07
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-4.59
Industry PE ratio
10.127857142857144
P/B Ratio
0PEG Ratio
-0.0969
EBITDA
-501.9M
Revenue (TTM)
52.9M
Profit Margin
0.00%
Return On Equity TTM
64138800.00%
Track how Intellia Therapeutics Inc. P/E has moved over time to understand its valuation trends.
Intellia Therapeutics Inc. in the last 5 years
Lowest (0.00x)
September 17, 2025
Today (-4.59x)
September 17, 2025
Industry (10.13x)
September 17, 2025
Highest (0.00x)
September 17, 2025
Today’s Price to Earnings Ratio: -4.59x
Compare market cap, revenue, PE, and other key metrics of Intellia Therapeutics Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $1.2B | -45.35% | -4.59 | 0.00% | |
BUY | $60.5B | 252.04% | -505.15 | -12.96% | |
NA | $39.0B | NA | NA | -3.89% | |
BUY | $100.3B | 44.17% | 27.85 | 31.86% | |
BUY | $59.6B | 1.78% | 14.1 | 31.37% |
The Intellia Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Intellia Therapeutics Inc. investment value today
Current value as on today
₹61,184
Returns
Returns from Intellia Therapeutics Inc. Stock
Dollar Returns*
₹4,598 (+4.6%)
Based on 34 analysts
79.41%
Buy
20.59%
Hold
0.00%
Sell
Based on 34 analysts, 79.41% of analysts recommend a 'BUY' rating for Intellia Therapeutics Inc.. Average target price of $34.45
Get share price movements and forecasts by analysts on Intellia Therapeutics Inc..
What analysts predicted
62.96%UPSIDE
Target Price
$34.45
Current Price
$12.76
Analyzed by
34 Analysts
Target
$34.45
Intellia Therapeutics Inc. target price $34.45, a slight upside of 62.96% compared to current price of $12.76. According to 34 analysts rating.
Investment in Intellia Therapeutics Inc. Shares on INDmoney has dropped by -57.59% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Intellia Therapeutics Inc. Stock has decreased by -26% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Profit Spike
Netprofit is up for the last 5 quarters, -146.97M → -101.25M (in $), with an average increase of 9.8% per quarter
Price Rise
In the last 7 days, NTLA stock has moved up by 8.7%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.1% return, outperforming this stock by 113.7%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 197.8%
Revenue Fall
Revenue is down for the last 2 quarters, 16.62M → 14.24M (in $), with an average decrease of 14.3% per quarter
Organisation | Intellia Therapeutics Inc. |
Headquarters | 40 Erie Street, Cambridge, MA, United States, 02139 |
Industry | Health Technology |
CEO | Dr. John M. Leonard M.D. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Michael P. Dube | VP, CAO & Principal Accounting Officer |
Dr. Laura Sepp-Lorenzino Ph.D. | Special Advisor to the Chief Executive Officer |
Dr. Rachel E. Haurwitz Ph.D. | Co-Founder |
Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder & Member of Scientific Advisor Board |
Mr. Edward J. Dulac III | Executive Vice President, Chief Financial Officer and Treasurer |
Mr. James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary |
Dr. David Lebwohl M.D. | Executive VP & Chief Medical Officer |
Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board |
Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board |
Dr. John M. Leonard M.D. | President, CEO & Director |
Intellia Therapeutics Inc. share price today is $12.76 as on . Intellia Therapeutics Inc. share today touched a day high of $13.1 and a low of $12.6.
Intellia Therapeutics Inc. share touched a 52 week high of $23.76 on and a 52 week low of $5.9 on . Intellia Therapeutics Inc. stock price today i.e. is trending at $12.76,which is 46.30% down from its 52 week high and 116.27% up from its 52 week low.
Intellia Therapeutics Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Intellia Therapeutics Inc. (NTLA) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Intellia Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Intellia Therapeutics Inc. share’s latest price of $12.76 as on September 17, 2025 at 9:39 pm IST, you will get 0.7837 shares of Intellia Therapeutics Inc.. Learn more about
fractional shares .
Intellia Therapeutics Inc. stock has given -45.35% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?